Tsing Capital
VC Fund
Beijing, China
Tsing Capital is a private equity and venture capital arm of Tsinghua Holdings Co., Ltd. specializing in growth capital.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Tsing Capital invests in
Stages Tsing Capital invests in
Countries Tsing Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.8M–$50M
- Series C
- $14M–$187M
Investment Focus
Industry
- Electronics 8 (24%)
- Energy 6 (18%)
- Health Care 4 (12%)
- Manufacturing 4 (12%)
- Semiconductor 4 (12%)
Stage
- Series A 7 (21%)
- Series C 6 (18%)
- Funding Round 6 (18%)
- Series B 5 (15%)
- Seed 3 (9%)
Country
- China 14 (42%)
- United States 11 (33%)
- Canada 1 (3%)
- South Africa 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bobing Ren
Associate
|
Associate | Total investments: 8 | Find email | |
Brian Heimberg
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
|
Don Ye
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 0 | Find email | |
|
Kiwi Chen
Associate
|
Associate | Total investments: 0 | Find email | |
|
Patrick Tam
General Partner
|
General Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ionova Life Science
|
Ionova Life Science is an anti-tumor drug developer dedicated to the development of innovative types of tumor-targeted drugs and tumor immunomodulatory drugs, including oncology, immuno-oncology, and cardiac metabolic diseases. Force contact | $100M / Venture - Series Unknown / Aug 22, 2021 | |
Stemirna
|
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $170.1M / Jun 03, 2021 | |
|
Stemirna
|
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $187.4M / Series C / Jun 03, 2021 | |
3D Medicines
|
3D Medicines, we use individual’s genetic information to prevent, diagnose, and treat cancer. We develop personalized medicines according to target population’s genetic background, to increase efficacy and safety. | $212.6M / Private Equity / Oct 19, 2020 | |
Vion Technology
|
Vion Technology is a Chinese artificial intelligence firm specializing in machine vision. Vion Technology provides artificial intelligence products and solutions to sectors such as smart cities and business intelligence. Its products include a smart camera used to capture images of traffic violations, an intelligent video analysis terminal capableof face and age recognition for monitoring and counting people, and what it claims is the world’s smallest smart people counting camera. Vion Technology’s solutions allows traffic bureaus to automatically identify traffic violations, recognize the license plate numbers, and generate traffic violation tickets via screening surveillance camera footage. | $20M / Series B / Dec 08, 2017 | |
MagicMed
|
MagicMed provides heart health management and data services. | $1.4M / Seed / Sep 01, 2017 | |
WiBotic
|
WiBotic provides the most reliable wireless power and battery intelligence solutions to charge your aerial, mobile and aquatic robot systems.Using WiBotic wireless power and battery intelligence solutions, you can greatly enhance the working efficiency of your robot fleets and save significant money in charging and maintenance costs.Oursolutions include wireless power delivery, battery intelligence and fleet-level power management software. So we not only maximize the battery life of each battery we charge, we create an operational plan for the entire collection of batteries in your robot fleet.WiBotic wireless power and battery intelligence solutions are safe, reliable and scalable. And they are easy-to-implement and highly customizable for specific robot deployments. | $2.5M / Seed / Apr 26, 2017 | |
Sensoro
|
SENSORO is committed to uniting the physical and digital world with advanced sensing technologies. Connectivity with our environments at home, in public, at work, and everywhere in between, brings improved comfort, security, and health. It allows businesses to reduce operating costs and boost productivity. SENSORO’s Alpha Suite delivers acomprehensive solution to enhance our world and elevate our lives.The Alpha Suite forms an industrial-grade wireless sensor network that merges ultra-long-range communication with proximity Bluetooth Low Energy technology. With the Alpha Suite, SENSORO provides a simple to implement, easily managed and scaled system that is ideal for smart cities and buildings, asset tracking, energy management, and environmental monitoring. | $18M / Series B / Apr 24, 2017 | |
Pargo
|
Pargo is a convenient logistics solution that lets you collect and return parcels at Pargo parcel points throughout the country when it suits you best. | $854K / Mar 22, 2017 | |
Enevate
|
Enevate develops and licenses advanced silicon-dominant Li-ion battery technology for electric vehicles (EVs), with a vision to charging EVs as fast as refueling gas cars and accelerating their mass adoption. Enevate's pioneering advancements in silicon-dominant anodes and cells have resulted in its XFC-Energy® and HD-Energy® technology thatfeatures 5-minute extreme fast charging with high energy density, low temperature operation for cold climates, low cost and safety advantages over conventional graphite Li-ion batteries. Enevate, with a portfolio of 250 issued and in process, has raised over $110M from investors including Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital, Bangchak, and others. The company has its global headquarters in Irvine, California. For more information go to www.enevate.com. | $13.8M / Series C / Mar 15, 2017 | |
| See all 33 investments → | |||
Co-Investors
Venrock
3 deals together
3P Equity Partners
2 deals together
Advantech Capital
2 deals together
Capricorn Investment Group
2 deals together
CITIC Securities
2 deals together
Eastward Capital Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Tsing Capital invest in?
Tsing Capital invests primarily in Electronics, Energy and Health Care startups, most often at Series A and Series C stage. Most of the 33 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Tsing Capital's check size?
Tsing Capital typically joins rounds of $2.8M–$50M at Series A and $14M–$187M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tsing Capital participates in.
How do I contact Tsing Capital?
Public channels for Tsing Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tsing Capital?
The team at Tsing Capital includes Bobing Ren (Associate), Brian Heimberg (Investment Director) and Don Ye (Founder and Managing Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
